Scott, Varlli
Delatycki, Martin B.
Tai, Geneieve
Corben, Louise A. http://orcid.org/0000-0001-8767-4582
Funding for this research was provided by:
Friedreich's Ataxia Research Alliance
University of Melbourne
Article History
Accepted: 18 July 2024
First Online: 8 August 2024
Declarations
:
: Open access funding enabled and organized by CAUL and its Member Institutions. V.S. and L.A.C. receive funding support from the Friedreich Ataxia Research Alliance (USA) via the Australian Friedreich Ataxia Stem Cell and Gene Therapy Consortium.
: V.S. and G.T. do not report any conflicts of interest. M.B.D. and L.A.C. were the Principal Investigator and Co-Investigator respectively for the clinical trial for Resveratrol (funded by the National Health and Medical Research Council (NHMRC) project grant 1102207). M.B.D. receives funding from PTC Therapeutics and Biogen to conduct clinical trials. L.A.C. provides consultancy services to Biogen Inc.
: Not applicable.
: Not applicable.
: Not applicable.
: All data generated or analysed during this study are included in this published article.
: Not applicable.
: V.S. and L.A.C. conceived and designed the work, completed the literature review and analysis and prepared the first manuscript draft. G.T. and M.B.D. contributed to literature review and analysis and provided critical review of manuscript drafts. All authors have read and approve the final version of the manuscript and agree to be accountable for the work.